No Data
Shengda Biotech: Zhejiang Shengda Biopharmaceutical Co., Ltd. 2024 Annual Results Pre-Profit Announcement
Zhejiang Shengda Biopharmaceutical Co., Ltd. 2024 Annual Results Pre-Profit Announcement
Zhejiang Shengda Bio-Pharm (603079.SH): It is expected that the net income in 2024 will be between 26 million yuan and 36 million yuan, achieving a turnaround from loss to profit year-on-year.
On January 20, Gelonghui reported that Zhejiang Shengda Bio-Pharm (603079.SH) announced that, according to preliminary estimates by the company's finance department, it is expected that the net income attributable to the owners of the parent company for the fiscal year 2024 will be between 26 million yuan and 36 million yuan. This marks a return to profitability compared to the same period last year (statutory disclosure data). It is expected that the net income attributable to the owners of the parent company, excluding non-recurring gains and losses, will be between 18 million yuan and 26 million yuan. During the reporting period, the company focused on refined management and technological upgrades, achieving cost reduction and efficiency enhancement. At the same time, the company deepened its differentiated competition strategy and further developed.
On December 30th, A-share investment shields︱Kangxi Communication: Shareholder Yancheng Semiconductors and Gongqingcheng Kangsheng plan to reduce their Shareholding by no more than 3%.
Shareholders of Zhejiang Shengda Bio-Pharm, Wanjian Investment, plan to reduce their shareholding by no more than 3%; multiple shareholders of Montage Technology plan to collectively reduce their shareholding by no more than 2%; South Chip Technology has cumulatively reduced its shareholding by 1% in Shanghai; shareholders of Kangxi Communication, Yancheng Semiconductors and Gongqingcheng Kangsheng, plan to reduce their shareholding by no more than 3%; Jiangsu Zhongshe Group has terminated its plan for a significant asset restructuring; First Tractor has terminated its significant asset sale; Kexing Biopharm has terminated the clinical trial of its interferon α2b spray.
Zhejiang Shengda Bio-Pharm (603079.SH): Wanjian Investment plans to shareholding no more than 3% of its shares.
Gelonghui reported on December 27 that Zhejiang Shengda Bio-Pharm (603079.SH) announced that Wanjian Investment plans to reduce its shareholding in the company by no more than 5,135,668 shares within three months after 15 trading days from the announcement of this shareholding reduction plan, with a reduction ratio not exceeding 3% of the company's total share capital.
Zhejiang Shengda Bio-Pharm (603079.SH) has successfully passed the Shanghai Stock Exchange's review for the issuance of stocks to specific individuals.
Zhejiang Shengda Bio-Pharm (603079.SH) announced that the company recently received a notice from the Shanghai Stock Exchange listing review center "...
Zhejiang Shengda Bio-Pharm Co., Ltd.'s (SHSE:603079) Shares Bounce 26% But Its Business Still Trails The Industry
